Time-dependent inhibition and induction of human cytochrome P4503A4/5 by an Oral IAP antagonist, LCL161, in vitro and in vivo in healthy subjects

Journal of Clinical Pharmacology

Volumn 53, Issue 6, 2013, Pages 642-653

  Dhuria, Shyeilla ^a   Einolf, Heidi ^b   Mangold, James ^b   Sen, Suman ^a   Gu, Helen ^b   Wang, Lai ^b   Cameron, Scott ^c   Dhuria, Shyeilla V ^a  

^a NOVARTIS PHARMA AG   (Switzerland)

^b NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^c NOVARTIS PHARMA K K   (Japan)

Author keywords

CYP3A induction; CYP3A time dependent inhibition; Drug drug interaction modeling; Midazolam; Pharmacokinetics

Indexed keywords

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; INHIBITOR OF APOPTOSIS PROTEIN; INHIBITOR OF APOPTOSIS PROTEIN ANTAGONIST; LCL 161; MESSENGER RNA; MIDAZOLAM; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; BODY MASS; CONTROLLED STUDY; CYTOKINE RELEASE SYNDROME; DIZZINESS; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVITY; ENZYME INACTIVATION; ENZYME INDUCTION; FEMALE; HEPATOMA CELL; HUMAN; HUMAN CELL; HUMAN EXPERIMENT; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL; LIVER MICROSOME; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; REPORTER GENE; RISK ASSESSMENT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION;

ADULT; AREA UNDER CURVE; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME INDUCTION; ENZYME INHIBITORS; FEMALE; HEPATOCYTES; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; MALE; MICROSOMES, LIVER; MIDAZOLAM; MIDDLE AGED; MODELS, BIOLOGICAL; RECEPTORS, STEROID; RNA, MESSENGER; THIAZOLES; TIME FACTORS; YOUNG ADULT;

EID: 84880315330     PISSN: 00912700     EISSN: 15524604     Source Type: Journal    
DOI: 10.1002/jcph.79     Document Type: Article

References (21)

1. Fulda S, Vucic D. Targeting IAP proteins for therapeutic intervention in cancer. Nat Rev Drug Disc. 2012;11:109-124.
2. Gyrd Hansen M, Meier P. IAPs: from caspase inhibitors to modulators of NF kB, inflammation and cancer. Nat Rev Cancer. 2010;10:561-574.
3. Gaither A, Porter D, Yao Y, et al. A smac mimetic rescue screen reveals roles for inhibitor of apoptosis proteins in tumor necrosis factor alpha signaling. Cancer Res. 2007;67:11493-11498.
4. Varfolomeev E, Blankenship JW, Wayson SM, et al. IAP antagonists induce autoubiquitination of c IAPs, NF kappaB activation, and TNFalpha dependent apoptosis. Cell. 2007;131:669-681.
5. Vince JE, Wong WW, Khan N, et al. IAP antagonists target cIAP1 to induce TNFalpha dependent apoptosis. Cell. 2007;131:682-693.
6. Infante JR, Dees EC, Olszanski AJ, et al. phase I dose escalation study of LCL161, an oral IAP inhibitor, in patients with advanced solid tumors. In preparation.
7. Murray M. Drug mediated inactivation of cytochrome P450. Clin Exp Pharmacol Physiol. 1997;24:465-470.
8. von Moltke LL, Greenblatt DJ, Schmider J, et al. Midazolam hydroxylation by human liver microsomes in vitro: inhibition by fluoxetine, norfluoxetine, and by azole antifungal agents. J Clin Pharmacol. 1996;36:783-791.
9. Ghosal A, Satoh H, Thomas PE, Bush E, Moore D. Inhibition and kinetics of cytochrome P4503A activity in microsomes from rat, human, and cdna expressed human cytochrome P450. Drug Metab Dispos. 1996;24:940-947.
10. Mayhew BS, Jones DR, Hall SD. An in vitro model for predicting in vivo inhibition of cytochrome P450 3A4 by metabolic intermediate complex formation. Drug Metab Dispos. 2000;28: 1031-1037.
11. Obach RS, Walsky RL, Venkatakrishnan K. Mechanism based inactivation of human cytochrome p450 enzymes and the prediction of drug drug interactions. Drug Metab Dispos. 2007;35:246-255.
12. Venkatakrishnan K, Obach RS. Drug drug interactions via mechanism based cytochrome P450 inactivation: points to consider for risk assessment from in vitro data and clinical pharmacologic evaluation. Curr Drug Metab. 2007;8:449-462.
13. McCrea J, Prueksaritanont T, Gertz BJ, et al. Concurrent administration of the erythromycin breath test (EBT) and oral midazolam as in vivo probes for CYP3A activity. J Clin Pharmacol. 1999;39:1212-1220.
14. Grimm SW, Einolf HJ, Hall SD, et al. The conduct of in vitro studies to address time dependent inhibition of drug metabolizing enzymes: a perspective of the pharmaceutical research and manufacturers ofAmerica. Drug Metab Dispos. 2009;37:1355-1370.
15. Nettleton DO, Einolf HJ. Assessment of cytochrome P450 enzyme inhibition and inactivation in drug discovery and development. Curr Topics Med Chem. 2011;11:382-403.
16. Stoch SA, Friedman E, Maes A, et al. Effect of different durations of ketoconazole dosing on the single dose pharmacokinetics of midazolam: shortening the paradigm. J Clin Pharmacol. 2009;49:398- 406.
17. Olkkola KT, Backman JT, Neuvonen PJ. Midazolam should be avoided in patients receiving the systemic antimycotics ketoconazole or itraconazole. Clin Pharmacol Ther. 1994;55:481-485.
18. Tsunoda SM, Velez RL, von Moltke LL, Greenblatt DJ. Differentiation of intestinal and hepatic cytochrome P450 3A activity with use of midazolam as an in vivo probe: effect of ketoconazole. Clin Pharmacol Ther. 1999;66:461-471.
19. Branch RA, Adedoyin A, Frye RF, Wilson JW, Romkes M. In vivo modulation of CYP enzymes by quinidine and rifampin. Clin Pharmacol Ther. 2000;68:401-411.
20. Morgan ET. Regulation of cytochrome P450 by inflammatory mediators: why how? DMD. 2001;29:207-212.
21. Renton KW. Cytokines and pharmacokinetic drug interactions. In: House RV, Descotes J, eds. Cytokines in Human Health: Immunotoxicity, Pathology, and Therapeutic Applications. Totowa, NJ: Humana Press; 2007: 275-296.